BIOMAT Database Logo BIOMAT Database Logo

Heparin modifies platelet count and function in patients who have undergone thrombolytic therapy for acute myocardial infarction. 1993

C L Balduini, and P Noris, and G Bertolino, and M Previtali

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D010979 Platelet Function Tests Laboratory examination used to monitor and evaluate platelet function in a patient's blood. Function Test, Platelet,Function Tests, Platelet,Platelet Function Test,Test, Platelet Function,Tests, Platelet Function
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013300 Streptokinase Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-. Avelizin,Awelysin,Celiase,Distreptase,Kabikinase,Kabivitrum,Streptase,Streptodecase
D015539 Platelet Activation A series of progressive, overlapping events, triggered by exposure of the PLATELETS to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug. Activation, Platelet,Activations, Platelet,Platelet Activations
D015912 Thrombolytic Therapy Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts. Fibrinolytic Therapy,Thrombolysis, Therapeutic,Therapeutic Thrombolysis,Therapy, Fibrinolytic,Therapy, Thrombolytic,Fibrinolytic Therapies,Therapeutic Thrombolyses,Therapies, Fibrinolytic,Therapies, Thrombolytic,Thrombolyses, Therapeutic,Thrombolytic Therapies

Related Publications

C L Balduini, and P Noris, and G Bertolino, and M Previtali
Blood viscosity and platelet function in thrombolytic therapy of acute myocardial infarction.
August 1990, European heart journal,
C L Balduini, and P Noris, and G Bertolino, and M Previtali
Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction.
February 1987, The American journal of cardiology,
C L Balduini, and P Noris, and G Bertolino, and M Previtali
Thrombolytic therapy for patients with acute myocardial infarction.
March 1987, The American journal of the medical sciences,
C L Balduini, and P Noris, and G Bertolino, and M Previtali
Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy.
August 1991, Annals of internal medicine,
C L Balduini, and P Noris, and G Bertolino, and M Previtali
Thrombolytic therapy for acute myocardial infarction in older patients.
April 1996, Lancet (London, England),
C L Balduini, and P Noris, and G Bertolino, and M Previtali
Thrombolytic therapy for acute myocardial infarction in older patients.
March 1996, Lancet (London, England),
C L Balduini, and P Noris, and G Bertolino, and M Previtali
[Indirect criteria of coronary reperfusion and permeability in patients with acute myocardial infarction who have received thrombolytic therapy].
March 1991, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology,
C L Balduini, and P Noris, and G Bertolino, and M Previtali
Thrombolytic therapy for acute myocardial infarction.
August 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,
C L Balduini, and P Noris, and G Bertolino, and M Previtali
Thrombolytic therapy for acute myocardial infarction.
October 2003, Saudi medical journal,
C L Balduini, and P Noris, and G Bertolino, and M Previtali
Thrombolytic therapy for acute myocardial infarction.
April 1989, Journal of the Tennessee Medical Association,
Copied contents to your clipboard!